

DAFTAR PUSTAKA

1. Schorge JO, Williams JW, eds. *MENOPAUSAL TRANSITION*. McGraw-Hill Medical; 2008.
2. Peña AS, Witchel SF, Hoeger KM, et al. Adolescent polycystic ovary syndrome according to the international evidence-based guideline. *BMC Med*. 2020;18(1):72. doi:10.1186/s12916-020-01516-x
3. Setiawati I, Purwanto B, Muhammad M. Effects of Moringa oleifera Leaf Extract to Risk of Endometrial Hyperplasia in Polycystic Ovary Syndrome Model with Insulin Resistance. *J Int Dent Med Res*. 2018;11(3):1123-1129.
4. Desmawati, Febri RR, Hestiantoro A, Asmarinah. DNA methylation of the androgen receptor gene promoter in the granulosa cells of polycystic ovary syndrome patients. *J Phys: Conf Ser*. 2018;1073:032078. doi:10.1088/1742-6596/1073/3/032078
5. Dadachanji R, Shaikh N, Mukherjee S. Genetic Variants Associated with Hyperandrogenemia in PCOS Pathophysiology. *Genetics Research International*. 2018;2018:1-12. doi:10.1155/2018/7624932
6. Branavan U, Muneeswaran K, Wijesundera S, Jayakody S, Chandrasekharan V, Wijeyaratne C. Identification of selected genetic polymorphisms in polycystic ovary syndrome in Sri Lankan women using low cost genotyping techniques. *plos one*. Published online 2018:19.
7. Roe AH, Dokras A. The Diagnosis of Polycystic Ovary Syndrome in Adolescents. :7.
8. Kamboj MK, Bonny AE. Polycystic ovary syndrome in adolescence: diagnostic and therapeutic strategies. *Transl Pediatr*. 2017;6(4):248-255. doi:10.21037/tp.2017.09.11
9. Oliveira A, Sampaio B, Teixeira A, Castro-Correia C, Fontoura M, Luís Medina J. Polycystic ovary syndrome: Challenges in adolescence. *Endocrinología y Nutrición*. 2010;57(7):328-336. doi:10.1016/j.endonu.2010.04.007
10. Witchel SF, Oberfield SE, Peña AS. Polycystic Ovary Syndrome: Pathophysiology, Presentation, and Treatment With Emphasis on Adolescent Girls. *Journal of the Endocrine Society*. 2019;3(8):1545-1573. doi:10.1210/js.2019-00078
11. Gao X ying. Role of Androgen Receptor for Reconsidering the “True” Polycystic Ovarian Morphology in PCOS. *Scientific Reports*. Published online 2020:7.

12. Caldwell ASL, Edwards MC, Desai R, et al. Neuroendocrine androgen action is a key extraovarian mediator in the development of polycystic ovary syndrome. *Proc Natl Acad Sci USA*. 2017;114(16):E3334-E3343. doi:10.1073/pnas.1616467114
13. Polat S. The role of androgen receptor CAG repeat polymorphism in androgen excess disorder and idiopathic hirsutism. *Journal of Endocrinological Investigation*. Published online 2020:11. doi:https://doi.org/10.1007/s40618-020-01215-7
14. Lardone MC, Castro A, Pereira A, Corvalán C, Ortíz E, Mericq V. Role of the Androgen Receptor Gene CAG Repeat Polymorphism on the Sequence of Pubertal Events and Adiposity in Girls with High Dehydroepiandrosterone Sulfate Level. *Journal of Pediatric and Adolescent Gynecology*. 2019;32(3):271-277. doi:10.1016/j.jpag.2018.11.012
15. Peng CY, Xie HJ, Guo ZF, et al. The association between androgen receptor gene CAG polymorphism and polycystic ovary syndrome: a case-control study and meta-analysis. *J Assist Reprod Genet*. 2014;31(9):1211-1219. doi:10.1007/s10815-014-0286-0
16. Shah NA, Antoine HJ, Pall M, Taylor KD, Azziz R, Goodarzi MO. Association of Androgen Receptor CAG Repeat Polymorphism and Polycystic Ovary Syndrome. *The Journal of Clinical Endocrinology & Metabolism*. 2008;93(5):1939-1945. doi:10.1210/jc.2008-0038
17. BPS. Jumlah Penduduk Umur Sekolah Menurut Jenis Kelamin Tahun 2017. Published 2018. <https://sumbar.bps.go.id/statictable/2018/04/17/423/jumlah-penduduk-umur-sekolah-sumatera-barat-menurut-jenis-kelamin-dan-kabupaten-kota-tahun-2017.html>
18. Kemdikbud. JUMLAH DATA SATUAN PENDIDIKAN (SEKOLAH) PER KABUPATEN/KOTA : Kota Padang. Data Referensi. Published 2021. <https://referensi.data.kemdikbud.go.id/index11.php?kode=086100&level=2>
19. McCartney CR, Marshall JC. Polycystic Ovary Syndrome. Solomon CG, ed. *N Engl J Med*. 2016;375(1):54-64. doi:10.1056/NEJMcp1514916
20. Dunaif A, ed. *Polycystic Ovary Syndrome: Current Controversies, from the Ovary to the Pancreas*. Humana; 2008.
21. Alsadi B. Polycystic Ovary Syndrome, Pathophysiology, and Reproductive Health Implications. In: Gaze DC, ed. *Pathophysiology - Altered Physiological States*. InTech; 2018. doi:10.5772/intechopen.70848
22. Mauro Cozzolino, Amerigo Vitagliano, Livia Pellegrini. Therapy with probiotics and synbiotics for polycystic ovarian syndrome: a systematic review and meta-analysis. *European Journal of Nutrition*. Published online 2020.

23. Balen AH. Polycystic ovary syndrome (PCOS). *Obstet Gynecol.* 2017;19(2):119-129. doi:10.1111/tog.12345
24. Edmonds DK, Dewhurst J, eds. *Dewhurst's Textbook of Obstetrics & Gynaecology*. 7th ed. Blackwell Pub; 2007.
25. Ahmadi S, Jamilian M, Karamali M, et al. Probiotic supplementation and the effects on weight loss, glycaemia and lipid profiles in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. *Human Fertility*. 2017;20(4):254-261. doi:10.1080/14647273.2017.1283446
26. Rosenfield RL, Ehrmann DA. The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited. *Endocrine Reviews*. 2016;37(5):467-520. doi:10.1210/er.2015-1104
27. Owens LA, Kristensen SG, Lerner A, et al. Gene Expression in Granulosa Cells From Small Antral Follicles From Women With or Without Polycystic Ovaries. *The Journal of Clinical Endocrinology & Metabolism*. 2019;104(12):6182-6192. doi:10.1210/jc.2019-00780
28. Bani Mohammad M, Majdi Seghinsara A. Polycystic Ovary Syndrome (PCOS), Diagnostic Criteria, and AMH. *APJCP*. 2017;18(1). doi:10.22034/APJCP.2017.18.1.17
29. Anagnostis P, Tarlatzis BC, Kauffman RP. Polycystic ovarian syndrome (PCOS): Long-term metabolic consequences. *Metabolism*. 2018;86:33-43. doi:10.1016/j.metabol.2017.09.016
30. Rosenfield RL, Ehrmann DA. The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited. *Endocrine Reviews*. 2016;37(5):467-520. doi:10.1210/er.2015-1104
31. Hoffman BL, Schorge JO, Bradshaw KD, Halvorson LM, Schaffer JI, Corton MM. *Williams Gynecology*.; 2016.
32. Rodriguez Paris V, Bertoldo MJ. The Mechanism of Androgen Actions in PCOS Etiology. *Medical Sciences*. 2019;7(9):89. doi:10.3390/medsci7090089
33. Hoeger KM, Oberfield SE. Do women with PCOS have a unique predisposition to obesity? *Fertility and Sterility*. 2012;97(1):13-17. doi:10.1016/j.fertnstert.2011.11.026
34. Lucidi RS. Polycystic Ovarian Syndrome Treatment & Management: Approach Considerations, Lifestyle Modifications, Drug Treatment. Published online May 11, 2020. Accessed July 13, 2020. <https://emedicine.medscape.com/article/256806-treatment>
35. P. K, A. H. The cut off of Ferriman Gallwey score for PCOS in Asia and the degree of hyperandrogenism indicator. *Kme*. 2017;1(1):186. doi:10.18502/kme.v1i1.640

36. Lizneva D, Suturina L, Walker W, Brakta S, Gavrilova-Jordan L, Azziz R. Criteria, prevalence, and phenotypes of polycystic ovary syndrome. *Fertility and Sterility*. 2016;106(1):6-15. doi:10.1016/j.fertnstert.2016.05.003
37. Christakou C, Diamanti-Kandarakis E. Polycystic ovary syndrome – Phenotypes and diagnosis. *Scandinavian Journal of Clinical and Laboratory Investigation*. 2014;74(sup244):18-22. doi:10.3109/00365513.2014.936675
38. Azziz R, Kintziger K, Li R, et al. Recommendations for epidemiologic and phenotypic research in polycystic ovary syndrome: an androgen excess and PCOS society resource. *Human Reproduction*. 2019;34(11):2254-2265. doi:10.1093/humrep/dez185
39. Lanzo E, Monge M, Trent M. Diagnosis and Management of Polycystic Ovary Syndrome in Adolescent Girls. *Pediatr Ann*. 2015;44(9):e223-e230. doi:10.3928/00904481-20150910-10
40. Lua A, How C, King T. Managing polycystic ovary syndrome in primary care. *smedj*. Published online November 2018;567-571. doi:10.11622/smedj.2018135
41. Boyle J, Teede, Helena J. Polycystic ovary syndrome – an update. *Australian Family Physician*. 2012;40(10):752-756.
42. HIFERI. Konsensus Tatalaksana Sindrom Ovarium Polikistik. Published online 2016.
43. Kabel AM. Polycystic ovarian syndrome: insights into pathogenesis, diagnosis, prognosis, pharmacological and non-pharmacological treatment. Published online 2016:6.
44. Chang C, Lee SO, Wang RS, Yeh S, Chang TM. Androgen Receptor (AR) Physiological Roles in Male and Female Reproductive Systems: Lessons Learned from AR-Knockout Mice Lacking AR in Selective Cells1. *Biology of Reproduction*. 2013;89(1). doi:10.1095/biolreprod.113.109132
45. Davey RA, Grossmann M. Androgen Receptor Structure, Function and Biology: From Bench to Bedside. :13.
46. Walters KA. Polycystic ovary syndrome: Is it androgen or estrogen receptor? *Current Opinion in Endocrine and Metabolic Research*. 2020;12:1-7. doi:10.1016/j.coemr.2020.01.003
47. Franks S, Hardy K. Androgen Action in the Ovary. *Front Endocrinol*. 2018;9:452. doi:10.3389/fendo.2018.00452
48. Abbott DH. Neuronal androgen receptor: Molecular gateway to polycystic ovary syndrome? *Proc Natl Acad Sci USA*. 2017;114(16):4045-4047. doi:10.1073/pnas.1703436114

49. Yuan C, Gao C, Qian Y, et al. Polymorphism of CAG and GGN repeats of androgen receptor gene in women with polycystic ovary syndrome. *Reproductive BioMedicine Online*. 2015;31(6):790-798. doi:10.1016/j.rbmo.2015.09.007
50. Baculescu N. The role of androgen receptor activity mediated by the CAG repeat polymorphism in the pathogenesis of PCOS. *Journal of Medicine and Life*. 2013;6(1):18-25.
51. Saddick SY. Identifying genes associated with the development of human polycystic ovary syndrome. *Saudi Journal of Biological Sciences*. 2020;27(5):1271-1279. doi:10.1016/j.sjbs.2020.01.012
52. Tian L, Zou Y, Tan J, et al. Androgen receptor gene mutations in 258 Han Chinese patients with polycystic ovary syndrome. *Exp Ther Med*. 2020;21(1):1-1. doi:10.3892/etm.2020.9463
53. Notoatmodjo S. *Metodologi Penelitian Kesehatan*. Rineka Cipta; 2010.
54. Charan J, Biswas T. How to calculate sample size for different study designs in medical research? *Indian J Psychol Med*. 2013;35(2):121. doi:10.4103/0253-7176.116232
55. Mastoroh I, Anggita N. *Bahan Ajar Rekam Medis Dan Informasi Kesehatan; Metodologi Penelitian Kesehatan*. Kementerian Kesehatan RI; 2018.
56. Kementerian Kesehatan RI. Klasifikasi Obesitas setelah pengukuran IMT. <http://p2ptm.kemkes.go.id/infographic-p2ptm/obesitas/klasifikasi-obesitas-setelah-pengukuran-imt>
57. Batubara JR. Acanthosis Nigricans dan Hubungannya dengan Resistensi Insulin pada Anak dan Remaja. *SP*. 2016;12(2):67. doi:10.14238/sp12.2.2010.67-73
58. Burke JP, Hale DE, Hazuda HP, Stern MP. A quantitative scale of acanthosis nigricans. *Diabetes Care*. 1999;22(10):1655-1659. doi:10.2337/diacare.22.10.1655
59. Kemendikbud. Statistik Pendidikan. Published 2022. <https://statistik.data.kemdikbud.go.id/assets/index2.html>
60. BPS. Laporan Survei Demografi dan Kesehatan Indonesia, 2017. Badan Pusat Statistik. Published 2020. <https://www.bps.go.id/statictable/2020/10/21/2111/laporan-survei-demografi-dan-kesehatan-indonesia.html>
61. Barber TM, Hanson P, Weickert MO, Franks S. Obesity and Polycystic Ovary Syndrome: Implications for Pathogenesis and Novel Management Strategies. *Clin Med Insights Reprod Health*. 2019;13:117955811987404. doi:10.1177/1179558119874042

62. Malavige LS, Jayawickrama S, Ranasinghe P, Levy JC. Androgen receptor CAG repeat polymorphism is not associated with insulin resistance and diabetes among South Asian males. *BMC Res Notes*. 2017;10(1):685. doi:10.1186/s13104-017-3035-5
63. Dasgupta S, Sirisha PVS, Neelaveni K, et al. Androgen Receptor CAG Repeat Polymorphism and Epigenetic Influence among the South Indian Women with Polycystic Ovary Syndrome. Dubé MP, ed. *PLoS ONE*. 2010;5(8):e12401. doi:10.1371/journal.pone.0012401
64. Jääskeläinen J, Korhonen S, Voutilainen R, Hippeläinen M, Heinonen S. Androgen receptor gene CAG length polymorphism in women with polycystic ovary syndrome. *Fertility and Sterility*. 2005;83(6):1724-1728. doi:10.1016/j.fertnstert.2004.11.080
65. Laisk T, Haller-Kikkatalo K, Laanpere M, et al. Androgen receptor epigenetic variations influence early follicular phase gonadotropin levels. *Acta Obstet Gynecol Scand*. 2010;89(12):1557-1563. doi:10.3109/00016349.2010.526182



